JPH0217113A - Externally applying agent for skin - Google Patents
Externally applying agent for skinInfo
- Publication number
- JPH0217113A JPH0217113A JP63167464A JP16746488A JPH0217113A JP H0217113 A JPH0217113 A JP H0217113A JP 63167464 A JP63167464 A JP 63167464A JP 16746488 A JP16746488 A JP 16746488A JP H0217113 A JPH0217113 A JP H0217113A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- keratinization
- rate
- ribosomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 claims abstract description 88
- 230000003780 keratinization Effects 0.000 claims description 45
- 210000003705 ribosome Anatomy 0.000 claims description 38
- 210000003491 skin Anatomy 0.000 claims description 32
- 241000207929 Scutellaria Species 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 20
- 210000002615 epidermis Anatomy 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 30
- 230000007306 turnover Effects 0.000 abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000006003 cornification Effects 0.000 abstract description 3
- 241000282994 Cervidae Species 0.000 abstract description 2
- 241000282985 Cervus Species 0.000 abstract description 2
- 241000207923 Lamiaceae Species 0.000 abstract description 2
- 239000002502 liposome Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 210000000434 stratum corneum Anatomy 0.000 description 29
- 239000006071 cream Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 239000008347 soybean phospholipid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000008344 egg yolk phospholipid Substances 0.000 description 6
- 229940068998 egg yolk phospholipid Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- -1 Polyoxyethylene Polymers 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002795 fluorescence method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 3
- 241001061526 Pluteus cervinus Species 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000000736 corneocyte Anatomy 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 description 2
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、新規な皮膚外用剤に関するものである。さら
に詳しくは、ロクジヨウ抽出液、オウゴン抽出液をリボ
ソーム化し有効成分として含有せしめ、皮膚表皮の角化
を正常化することを特徴とする化粧料に関するものであ
る。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a novel external preparation for skin. More specifically, the present invention relates to a cosmetic material that normalizes the keratinization of the skin epidermis by containing Rokujiyou extract and Scutellariae extract and Scutellariae extract as active ingredients in the form of ribosomes.
ロクジヨウ抽出液及びオウゴン抽出液を個々に化粧料に
配合している例はみられる。ロクジヨウ抽出液には心臓
機能の回復、腎機能の促進、消化器官系の機能促進、筋
肉の疲労回復等多数の作用が知られているが、皮膚表皮
の角化に及ぼす影響については研究された例は見られな
い。There are cases where Rokujiyo extract and Scutellaria scutellariae extract are individually blended into cosmetics. Rokujiyo extract is known to have a number of effects, including restoring heart function, promoting kidney function, promoting digestive system function, and recovering from muscle fatigue.However, its effect on keratinization of the skin epidermis has not been studied. No examples are seen.
また、オウゴン抽出液には消炎作用、解熱作用等が知ら
れているが、これも皮膚表皮の角化に及ぼす影響につい
ては研究された例は見られない。Scutellaria scutellariae extract is known to have anti-inflammatory and antipyretic effects, but no studies have been conducted on its effects on the keratinization of the skin epidermis.
さらに、ロクジヨウ抽出液を内包したリボソーム及びオ
ウゴン抽出液を内包したリボソームを化粧料に配合し、
皮膚表皮の角化を正常化するものは今まで見られない。Furthermore, ribosomes containing Rokujiyou extract and ribosomes containing Scutellaria scutellariae extract are blended into cosmetics,
Until now, nothing has been found that normalizes the keratinization of the skin epidermis.
皮膚の表皮を構成する細胞の大部分は、角化細胞(ケラ
チノサイト)とよばれ、この細胞は表皮の最下層にある
基底層で分裂して生まれ、次第に偏平化しながら有きよ
く層、か粒層へと押し上げられ、14日間かがって角質
層に到着して角質細胞になる(Jl胞屡のターンオーバ
ー)、この細胞はさらに14日間かかって上に押し上げ
られて、ついには角片となって皮膚表面から脱落する。Most of the cells that make up the epidermis of the skin are called keratinocytes.These cells are born by dividing in the basal layer, the lowest layer of the epidermis, and gradually become flattened and form fine layers and granules. It takes 14 days to reach the stratum corneum and become corneocytes (Jl cell turnover), and these cells take another 14 days to be pushed upwards and finally become corneum. Fall off from the skin surface.
この角質層の細胞が入れ替わることを角質層のターンオ
ーバーと言い、それに要する日数を角質層のターンオー
バー日数と言う、また有きよく層から角質層に移動する
間に角化細胞の形が変わっていき、角質層で核は消失す
る。このように角化細胞の総合的分化現象を角化と言う
、この角化によって表皮の細胞が入れ替わることを表皮
のターンオーバーと言い、正常な場合では細胞層のター
ンオーバーと角質層のターンオーバーを合計した28日
(表皮のターンオーバー日数)である、角質層は表皮の
一部であることから、当然の事ながら表皮のターンオー
バーは角質層のターンオーバーと密接な関係がある。従
って、角質層のターンオーバー日数を測定することによ
り1表皮の角化速度をみることができる0表皮の角化速
度が速くなるほど角質層のターンオーバー日数は短くな
る。This replacement of cells in the stratum corneum is called stratum corneum turnover, and the number of days required for this is called stratum corneum turnover days.It is also common for keratinocytes to change shape while moving from layer to layer. The nucleus disappears in the stratum corneum. This comprehensive differentiation phenomenon of keratinocytes is called keratinization, and the replacement of epidermal cells due to this keratinization is called epidermal turnover. In normal cases, cell layer turnover and stratum corneum turnover occur. Since the stratum corneum is a part of the epidermis, the turnover of the epidermis is naturally closely related to the turnover of the stratum corneum. Therefore, by measuring the number of days for turnover of the stratum corneum, the rate of keratinization of the epidermis can be seen. The faster the rate of keratinization of the epidermis, the shorter the number of days for turnover of the stratum corneum.
皮膚表皮の角化異常には2通りのものがある。There are two types of abnormal keratosis of the skin epidermis.
1つは加齢と共に起きるもので、細胞分裂の速度が遅く
なることにより表皮の角化速度が遅くなる(角質層のタ
ーンオーバー日数は長くなる)、このため表皮の細胞層
は薄くなり、逆に角質層が厚くなってくる。この結果と
して皮膚表面の水分量は減少し、弾力のある柔軟な皮膚
を失うことになる。老化した皮膚をみずみずしくするた
めには化粧水やクリームを塗って皮膚の水分を保つこと
がなされるが、根本的な解決にはならない。One is that it occurs with aging, as the rate of cell division slows down, which slows down the rate of cornification of the epidermis (the turnover of the stratum corneum increases), which causes the cell layer of the epidermis to become thinner, and vice versa. The stratum corneum becomes thicker. As a result, the amount of moisture on the skin surface decreases, resulting in a loss of elasticity and softness of the skin. In order to keep aging skin fresh, people apply lotions and creams to keep the skin moist, but this does not provide a fundamental solution.
もう1つの角化異常は、外部からの紫外線、乾燥や温度
変化等の影響により特に、頬や額では表皮細胞に変化が
生じて角化が正常に行われなくなり、逆に角化速度が異
常に早くなることがある(角質層のターンオーバー日数
は短くなる)、この結果1表皮細胞は角化が完成される
前に角質層に押し上げられ1本来、無核であるはずの角
質細胞に核が残るという現象が生ずる。正常な角化が行
われない場合にはNMFやセラミドが充分につくられず
、皮膚の水分保持能が低下して皮膚表面の水分量が減少
する。Another type of keratinization abnormality is that due to the effects of external ultraviolet rays, dryness, and temperature changes, changes occur in the epidermal cells of the cheeks and forehead, which prevents keratinization from occurring normally, and conversely, the rate of keratinization becomes abnormal. (The turnover period of the stratum corneum is shortened.) As a result, 1 epidermal cells are pushed up into the stratum corneum before keratinization is completed, and 1 the keratinocytes, which should originally be anucleated, have nuclei. A phenomenon occurs in which . When normal keratinization does not occur, sufficient NMF and ceramide are not produced, and the skin's ability to retain moisture decreases, resulting in a decrease in the amount of moisture on the skin surface.
このような異常に速くなったり、遅くなったりする角化
を正常化する化粧料は今まで全く見られない。Until now, no cosmetics have been found that normalize such abnormally rapid or slow keratinization.
本発明者らは、crクジヨウ抽出液を内包したリボソー
ムを配合した皮膚外用剤を表皮の角化速度の遅い(正常
な角質層のターンオーバー日数の14日より長い)皮膚
に使用すると角化速度が速くなり正常化する(正常な角
質層のターンオーバー日数の14日に近づく)ことを見
いだした。またオウゴン抽出液を内包したリボソームを
配合した皮膚外用剤を表皮の角化速度の速い(正常な角
質層のターンオーバー日数の14日より短く、角質細胞
に核が残る)皮膚に使用すると角化速度が遅くなり正常
化する(正常な角質層のターンオーバー日数の14日に
近づき、角質細胞の核が消失する)ことを見いだした。The present inventors found that when a topical skin preparation containing ribosomes containing CR Kujiyou extract was used on skin with a slow rate of epidermal keratinization (longer than 14 days, which is the normal turnover period of the stratum corneum), the rate of keratinization increased. It was found that the turnover rate became faster and normalized (approximately 14 days, which is the normal number of days for turnover of the stratum corneum). In addition, if a topical skin preparation containing ribosomes containing Scutellaria scutellariae extract is used on skin where the rate of epidermal keratinization is fast (shorter than the normal stratum corneum turnover period of 14 days, and nuclei remain in the keratinocytes), keratinization occurs. It was found that the rate slowed down and normalized (the normal turnover period of the stratum corneum approached 14 days, and the nuclei of the corneocytes disappeared).
さらにこれらのリボソームを併用して皮膚外用剤に配合
した場合は表皮の角化速度が遅い部位は速く、角化速度
が速い部位は遅くして正常化することを見いだし本発明
の完成に至った。Furthermore, when these ribosomes are combined in a skin preparation, it has been found that areas of the epidermis where the keratinization rate is slow is accelerated, and areas where the keratinization rate is fast is slowed down and normalized, leading to the completion of the present invention. .
本発明に用いられるロクジヨウ抽出液は、マンシュウア
カシカ(馬鹿)またはマンシュウシカ(梅花1!、)の
角化していない切角(鹿茸)をエタノール又はエタノー
ルと水の混合液で抽出したものである。またエタノール
以外の水溶性の溶剤、例えば1,3−ブチレングリコー
ル、プロピレングリコール等を用いて抽出することも可
能である。The extract used in the present invention is obtained by extracting the unhorned cut horns (deer mushrooms) of Manshu red deer (Fool) or Manshu deer (Plum blossom 1!) with ethanol or a mixture of ethanol and water. It is also possible to extract using a water-soluble solvent other than ethanol, such as 1,3-butylene glycol or propylene glycol.
本発明に用いられるオウゴン抽出液は、シソ科植物のコ
ガネバナ(黄金孔)の根(オウゴン)をエタノール又は
エタノールと水の混合液で抽出したものである。またエ
タノール以外の水溶性の溶剤、例えば1.3−ブチレン
グリコール、プロピレングリコール等を用いて抽出する
ことも可能である。The Scutellariae extract used in the present invention is obtained by extracting the roots (Scutellariae) of the Lamiaceae plant with ethanol or a mixture of ethanol and water. It is also possible to extract using a water-soluble solvent other than ethanol, such as 1,3-butylene glycol or propylene glycol.
本発明のリボソームはロクジヨウ抽出液または及びオウ
ゴン抽出液、リン脂質及び水の3成分に超音波をかけて
得られる。このリボソームはリン脂質の二分子膜の一重
層あるいは多重層から成る球状の小胞体で、ロクジヨウ
抽出液またはオウゴン抽出液がリン脂質の膜中または小
胞体内に取り込まれた状態(内包)となる。The ribosome of the present invention can be obtained by applying ultrasound to the three components of Rokujijo extract or Scutellaria scutellariae extract, phospholipid, and water. This ribosome is a spherical endoplasmic reticulum consisting of a single or multilayered bilayer membrane of phospholipids, and the extract of Rokujiyo or Scutellariae extract is taken into the membrane of phospholipids or within the endoplasmic reticulum (encapsulation). .
リボソームの安定化の目的でコレステロール。Cholesterol for the purpose of stabilizing ribosomes.
グルコース、アミノ酸、高級アルコール、非イオン性界
面活性剤、イオン性界面活性剤等を添加することができ
る。リボソーム化にはこれ以外にホモミキサー法、薄膜
法、注入法、界面活性剤除去法等がありどの方法におい
ても本発明のリボソームを調製することができる。Glucose, amino acids, higher alcohols, nonionic surfactants, ionic surfactants, etc. can be added. In addition to these methods, ribosomes can be produced by a homomixer method, a thin film method, an injection method, a surfactant removal method, etc., and the ribosomes of the present invention can be prepared by any of these methods.
リボソーム化に用いられるリン脂質は大豆リン脂質、卵
黄リン脂質、水添大豆リン脂質、水添卵黄リン脂質、合
成リン脂質等であり一種又は二種以上混合して用いるこ
とができる。The phospholipids used for ribosome formation are soybean phospholipids, egg yolk phospholipids, hydrogenated soybean phospholipids, hydrogenated egg yolk phospholipids, synthetic phospholipids, etc., and they can be used alone or in combination of two or more.
本発明において皮膚外用剤に配合されるリボソームに使
用するロクジヨウ抽出液は、ロクジヨウ抽出液の乾燥物
として0.0001〜0.2重量%である。0.0OO
1F!ffi%以下の配合量では効果は見られない、ま
た0、21重量%以上の配合量では効果の著しい増加は
見られず経済的ではない。In the present invention, the amount of Rokujiyo extract used in the ribosomes blended into the skin external preparation is 0.0001 to 0.2% by weight as a dry product of Rokujiyo extract. 0.0OO
1F! If the amount is less than ffi%, no effect will be observed, and if the amount is more than 0.21% by weight, no significant increase in effect will be observed and it is not economical.
本発明において皮膚外用剤に配合されるリボソームに使
用されるオウゴン抽出液は、オウゴン抽出液の乾燥物と
して0.0001〜0.1重量%である。o、oooi
重量%以下の配合量では効果は見られない、また0、2
重量%以上の配合量では効果の著しい増加は見られず経
済的ではない。In the present invention, the Scutellariae extract used in the ribosomes blended into the skin external preparation is 0.0001 to 0.1% by weight as a dry product of the Scutellariae extract. o, oooi
No effect is observed when the amount is less than 0.2% by weight.
If the amount is greater than % by weight, no significant increase in effectiveness is observed and it is not economical.
ロクジヨウ抽出液を内包したリボソーム及びオウゴン抽
出液を内包したリボソームの二種類を併用して皮膚外用
剤に配合する場合も、リボソームに使用するロクジヨウ
抽出液は、ロクジヨウ抽出液の乾燥物として0.000
1〜0.2重量%であり、リボソームに使用されるオウ
ゴン抽出液は、オウゴン抽出液の乾燥物として0.00
01〜0゜11i量%である。Even when combining two types of ribosomes, one containing Rokujiyo extract and the other containing Scutellaria scutellariae extract, into a skin preparation, the Rokujiyo extract used for the ribosome is 0.000% as a dry product of Rokujiyo extract.
1 to 0.2% by weight, and the Scutellariae extract used for ribosomes contains 0.00% as a dry product of Scutellaria extract.
01 to 0°11i amount%.
ロクジヨウ抽出液及びオウゴン抽出液をリボソーム化せ
ず、直接化粧料に配合した場合にはほとんど効果は見ら
れない、これは抽出物の有効成分が基底細胞に到達して
はじめて効果を発揮するためと考えられ、リボソーム化
することにより経皮吸収性が著しく高められるためと考
えられる。また、ロクジヨウ抽出液及びオウゴン抽出液
を混合してからリボソームにして皮膚外用剤に配合して
も効果は得られる。When Rokujiyou extract and Scutellaria scutellariae extract are directly blended into cosmetics without converting them into ribosomes, almost no effect is observed.This is because the active ingredients of the extracts do not exhibit their effects until they reach the basal cells. This is thought to be because transdermal absorption is significantly enhanced by ribosome formation. Furthermore, the effect can also be obtained by mixing the extract of Scutellariae and the extract of Scutellariae and then making the ribosomes into ribosomes and adding them to an external skin preparation.
次に実施例により本発明をさらに説明するが、本発明は
これにより限定されるものではない、処方中の数字は重
量%を示す。Next, the present invention will be further explained with reference to Examples, but the present invention is not limited thereto. The numbers in the formulations indicate weight %.
実施例−1クリーム1
■スクワラン
■セチルアルコール
■ポリオキシエチレン(20)
ソルビタンモノステアレート
■ポリオキシエチレン(20)
10、0
2.0
1.5
2.0
セチルエーテル
■ワセリン 5.0■
ミリスチン酸オクチルドデシル 10.O■精製水
49・ 3■1,3−ブ
チレングリコール 10.0■パラオキシ安息香
酸メチル 0.2[相]水添大豆リン脂質
0・ 20ロクジヨウ抽出液A
2,0@精製水
7.80クジヨウ抽出液Aは細切りしたマン
シュウアカシカの鹿茸100gを70%重量エタノール
水溶液900gに浸漬し、5日間放置後ろ過しエキスを
得る。ロクジヨウ抽出液Aの乾燥物は1.7重量%であ
る。リボソームは成分[相]〜@を75℃で超音波処理
し、30℃まで冷却して調製する。Example-1 Cream 1 ■ Squalane ■ Cetyl alcohol ■ Polyoxyethylene (20) Sorbitan monostearate ■ Polyoxyethylene (20) 10,0 2.0 1.5 2.0 Cetyl ether ■ Vaseline 5.0 ■
Octyldodecyl myristate 10. O ■ Purified water 49. 3 ■ 1,3-butylene glycol 10.0 ■ Methyl paraoxybenzoate 0.2 [Phase] Hydrogenated soybean phospholipid
0.20 Rokujiyo extract A
2,0 @purified water
7.80 Kujiyo extract A is obtained by immersing 100 g of finely chopped Aka deer mushroom in 900 g of a 70% weight ethanol aqueous solution and leaving it for 5 days to obtain a filtered extract. The dry matter of Rokujiyo extract A is 1.7% by weight. Ribosomes are prepared by sonicating the components [phase]~@ at 75°C and cooling to 30°C.
成分■〜■を80℃で加熱溶解後、あらかじめ80℃に
加熱溶解した成分■〜■を加えて乳化し。After heating and dissolving components 1 to 2 at 80°C, components 1 to 2 previously heated and dissolved at 80°C were added and emulsified.
30℃まで冷却し、成分[相]〜@で調製したリボソー
ム(ロクジヨウ抽出液の乾燥物として0.034を量%
)を添加し、撹はん混合するとクリーム1が得られる。Cool to 30°C and add 0.034% by weight of ribosomes prepared with ingredients [phase] ~ @ as dry matter of Rokujiyo extract.
) and stir to mix to obtain Cream 1.
実施例−2クリーム2
■スクワラン 10.0■セ
チルアルコール 2.00ポリオキ
シエチレン(20) 1.5ソルビタンモ
ノステアレート
■ポリオキシエチレン(20) 2.0セ
チルエーテル
■ワセリン 5.0■ミ
リスチン酸オクチルドデシル 10.00精製水
49.3■1,3−ブチレ
ングリコール 10.0■パラオキシ安息香酸メ
チル 0. 2[相]水添大豆リン脂質
0.20オウゴン抽出液A
2. 0@精製水
7.8オウゴン抽出液Aはオウゴン100gに
精製水600gを加え60℃に加温した後、エタノール
をIKgを加えて3日間放置後ろ過しエキスを得る。オ
ウゴン抽出液Aの乾燥物は2.1重量%である。リボソ
ームは成分[相]〜@を75℃で超音波処理し、30℃
まで冷却して調製する。Example-2 Cream 2 ■ Squalane 10.0 ■ Cetyl alcohol 2.00 Polyoxyethylene (20) 1.5 Sorbitan monostearate ■ Polyoxyethylene (20) 2.0 Cetyl ether ■ Vaseline 5.0 ■ Myristic acid Octyldodecyl 10.00 Purified water
49.3 ■ 1,3-butylene glycol 10.0 ■ Methyl paraoxybenzoate 0. 2 [Phase] Hydrogenated soybean phospholipid
0.20 Scutellariae extract A
2. 0@purified water
7.8 Scutellariae extract A is obtained by adding 600 g of purified water to 100 g of Scutellariae and heating to 60°C, then adding I kg of ethanol, leaving to stand for 3 days, and filtering to obtain an extract. The dry matter of Scutellariae extract A is 2.1% by weight. Ribosomes are produced by ultrasonicating the components [phase]~@ at 75℃ and then at 30℃.
Cool until ready.
成分■〜■を80℃で加熱溶解後、あらかじめ80℃に
加熱溶解した成分■〜■を加えて乳化し、30℃まで冷
却し、成分[相]〜0で調製したリボソーム(オウゴン
抽出液の乾燥物として0.042重量%)を添加し、撹
はん混合するとクリーム2が得られる。After heating and dissolving components ① to ① at 80℃, add components ③ to ① previously heated to 80℃ to emulsify, cool to 30℃, and dissolve the ribosome prepared with component [phase] ~ Cream 2 is obtained by adding 0.042% by weight (as dry matter) and stirring and mixing.
実施例−3乳液l
■スクワラン
■セチルアルコール
■ポリオキシエチレン(20)
ソルビタンモノステアレート
■グリセリルモノステアレート
■ステアリン酸
■セチルイソオクタノエート
■精製水
5.0
1.0
2.5
■プロピレングリコール 8.0■パラ
オキシ安息香酸メチル 0・ 2[相]卵黄
リン脂質 1600オウゴン抽
出液B 5,0@精製水
5.0オウゴン抽出液Bはオウゴ
ン100gにエタノールをIKgを加えて7日間放置後
ろ過しエキスを得る。オウゴン抽出液Bの乾燥物は2,
311量%である。リボソームは成分[相]〜@を50
℃でホモミキサーをかけ30℃まで冷却して調製する。Example-3 Emulsion l ■ Squalane ■ Cetyl alcohol ■ Polyoxyethylene (20) Sorbitan monostearate ■ Glyceryl monostearate ■ Stearic acid ■ Cetyl isooctanoate ■ Purified water 5.0 1.0 2.5 ■ Propylene Glycol 8.0 ■ Methyl paraoxybenzoate 0. 2 [Phase] Egg yolk phospholipid 1600 Scutellariae extract B 5.0 @ Purified water
5.0 Scutellariae extract B is obtained by adding I kg of ethanol to 100 g of Scutellariae, leaving it for 7 days, and then filtering it. The dry matter of Scutellariae extract B is 2,
The amount is 311%. Ribosome is a component [phase] ~ @ 50
Prepare by cooling to 30°C using a homomixer.
成分■〜■を80℃で加熱溶解後、あらかじめ80℃に
加熱溶解した成分■〜■を加えて乳化し、30℃まで冷
却し、成分[相]〜Oで11I製したリボソーム(オウ
ゴン抽出液の乾燥物として0.115重量%)を添加し
、撹はん混合すると乳液1が得られる。After heating and dissolving components ■ to ■ at 80°C, emulsifying them by adding components (0.115% by weight as dry matter) is added and mixed by stirring to obtain Emulsion 1.
実施例−4化粧水1
■エタノール
10、0
■1.3−ブチレングリコール 2.0■グリ
セリン 3.0■パラオキ
シ安息香酸メチル 0.2■精製水
74.8■合成リン脂質
0. 5■コレステロール
0.1■ロクジヨウ抽出液B
O85■精製水
8,90クジヨウ抽出液Bは細切りしたマンシュ
ウシカの鹿茸100gを50%1!量工タノール水溶液
900gに浸漬し、5日間放置後ろ過しエキスを得る。Example-4 Lotion 1 ■ Ethanol 10,0 ■ 1.3-butylene glycol 2.0 ■ Glycerin 3.0 ■ Methyl paraoxybenzoate 0.2 ■ Purified water
74.8■Synthetic phospholipids
0. 5 ■ Cholesterol
0.1■ Rokujiyo extract B
O85 ■ Purified water
8.90 Kujiyo Extract B is 50%1 of 100g of finely chopped Manshuushika deer mushrooms! The sample was immersed in 900 g of a quantified ethanol aqueous solution and left to stand for 5 days to obtain a filtered extract.
ロクジヨウ抽出液Bの乾燥物は1.6重量%である。リ
ボソームは成分■〜■を55℃で超音波処理し、30℃
まで冷却して調製する。The dry matter of Rokujiyo extract B is 1.6% by weight. Ribosomes are prepared by ultrasonicating components ■~■ at 55°C and then at 30°C.
Cool until ready.
成分■〜■を撹はん綻解後、成分■及び成分■〜■で調
製したリボソームを加え(ロクジヨウ抽出液の乾燥物と
して0.008重量%)、撹はん混合すると化粧水1が
得られる。After stirring and dissolving Ingredients ■ to ■, add Ingredients ■ and ribosomes prepared with Ingredients ■ to ■ (0.008% by weight as dry matter of Rokujiyo extract) and mix with stirring to obtain Lotion 1. It will be done.
実施例−5クリーム3 ■スクワラン。Example-5 Cream 3 ■Squalane.
■セチルアルコール
■ポリオキシエチレン(20)
ソルビタンモノステアレート
■ポリオキシエチレン(20)
セチルエーテル
■ワセリン
■ミリスチン酸オクチルドデシル
■精製水
■1,3−ブチレングリコール
■パラオキシ安息香酸メチル
[相]水添大豆リン脂質
■ロクジヨウ抽出液A
@精製水
[相]水添大豆リン脂質
■オウゴン抽出液A
■精製水
10、0
2.0
1.5
2、0
成分■〜■を80℃で加熱溶解後、あらかじめ80℃に
加熱溶解した成分■〜■を加えて乳化し、30℃まで冷
却し、成分[相]〜@で調製したロクジヨウ抽出液配合
のリボソーム及び成分@〜■で調製したオウゴン抽出液
配合のリボソームを添加し、撹はん混合するとクリーム
3が得られる。■Cetyl alcohol ■Polyoxyethylene (20) Sorbitan monostearate ■Polyoxyethylene (20) Cetyl ether ■Vaseline ■Octyldodecyl myristate ■Purified water ■1,3-butylene glycol ■Methyl paraoxybenzoate [phase] Hydrogenation Soybean phospholipids ■ Rokujiyo extract A @ Purified water [phase] Hydrogenated soybean phospholipids ■ Scutellaria extract A ■ Purified water 10,0 2.0 1.5 2,0 After heating and dissolving ingredients ■ to ■ at 80℃ , add ingredients ■~■ previously heated and dissolved at 80°C, emulsify them, cool to 30°C, and prepare ribosomes containing Rokujiyo extract prepared with ingredients [phase]~@ and Scutellaria scutellariae extract prepared with ingredients @~■. Cream 3 is obtained by adding the ribosomes and stirring to mix.
実施例−6乳液2
■スクワラン
■セチルアルコール
■ポリオキシエチレン(20)
ソルビタンモノステアレート
■グリセリルモノステアレート
■ステアリン酸
■セチルイソオクタノエート
■精製水
■プロピレングリコール
■パラオキシ安息香酸メチル
[相]卵黄リン脂質
■オウゴン抽出液B
@精製水
5.0
1.0
2.5
■大豆リン脂質 0.5[相]
ロクジヨウ抽出液A 0. 1■
ポリオキシエチレン(60) 0.2硬化
ヒマシ油
[相]精製水 9.2オ
ウゴン抽出液配合のリボソームは成分[相]〜@を50
℃で、ロクジヨウ抽出液配合のリボソームは成分@〜[
相]を60℃でホモミキサーをかけた後、30℃まで冷
却して調製する。Example-6 Emulsion 2 ■ Squalane ■ Cetyl alcohol ■ Polyoxyethylene (20) Sorbitan monostearate ■ Glyceryl monostearate ■ Stearic acid ■ Cetyl isooctanoate ■ Purified water ■ Propylene glycol ■ Methyl paraoxybenzoate [phase] Egg yolk phospholipid ■ Scutellaria extract B @ purified water 5.0 1.0 2.5 ■ Soybean phospholipid 0.5 [phase]
Rokujiyo extract A 0. 1■
Polyoxyethylene (60) 0.2 Hydrogenated castor oil [phase] Purified water 9.2 Ribosomes containing Scutellaria scutellariae extract have components [phase] ~@50
At ℃, the ribosomes containing Rokujiyo extract have the following components:
Phase] is heated to 60°C in a homomixer and then cooled to 30°C.
成分■〜■を80℃で加熱溶解後、あらかじめ80℃に
加熱溶解した成分■〜■を加えて乳化し、30℃まで冷
却し、成分[相]〜@で調製したオウゴン抽出液配合の
リボソーム(オウゴン抽出液の乾燥物として0.115
1i量%)及び成分@〜[相]で調製したロクジヨウ抽
出液配合のリボソーム(ロクジヨウ抽出液の乾燥物とし
て0.00171量%)を添加し、撹はん混合すると乳
液2が得られる。。After heating and dissolving components ■ to ■ at 80℃, adding components ■ to ■ previously heated and dissolving at 80℃ to emulsify, cooling to 30℃, and preparing ribosomes containing Scutellaria scutellariae extract prepared with ingredients [phase] ~ @. (0.115 as dry matter of scutellariae extract
Emulsion 2 is obtained by adding ribosomes (0.00171% by weight as a dry product of Rokujiyo extract) containing the Rokujiyou extract prepared in the components @ to [phase] and stirring and mixing. .
本発明の化粧料は、リボソーム化したロクジジウ抽出液
と、リボソーム化したオウゴン抽出液を単独または併用
して配合することにより、表皮の角化を正常化すること
に優れた化粧料である。The cosmetic of the present invention is a cosmetic that is excellent in normalizing epidermal keratinization by blending a ribosome-formed Scutellaria chinensis extract and a ribosome-formed Scutellaria scutellariae extract, either alone or in combination.
次ぎに、本発明の効果について表皮の角化速度正常化試
験及び角質細胞正常化試験の結果を示す。Next, the results of an epidermal keratinization rate normalization test and a keratinocyte normalization test regarding the effects of the present invention are shown.
(表皮の角化速度正常化試験)
1)リボソーム化ロクジヨウ抽出液に関する試験年齢4
0才以上の表皮の角化速度の遅い女性モニター60名を
被験者として、1グル一プ各15名づつ実施例−1及び
実施例−4、そして、下記の比較例−1、比較例−2の
クリームを2ケ月毎日使用させた。(Test for normalization of epidermal keratinization rate) 1) Test age 4 for ribosomal Rokujiyo extract
Example 1 and Example 4, and Comparative Example 1 and Comparative Example 2 below, with 60 female monitors aged 0 years or older with slow epidermal keratinization rate as subjects, 15 people in each group. The cream was used every day for two months.
2ケ月後の角質層のターンオーバーについてダンジルク
ロライド蛍光法にて改善度を測定した。Two months later, the degree of improvement in the turnover of the stratum corneum was measured using the Danzyl chloride fluorescence method.
(ダンジルクロライド蛍光法)
蛍光試薬のダンジルクロライドを白色ワセリンに5%分
散させ、直径10mmのフィンチャンノ(−で皮膚に2
4時間閉塞塗布し、角質層を蛍光染色する0次ぎに、極
大波長338nmの紫外線を照射し、ダンジルクロライ
ドにて蛍光染色処理された角質層の蛍光強度を計測器に
て、終日的に測定する。(Danzyl chloride fluorescence method) Disperse 5% of the fluorescent reagent danzyl chloride in white petrolatum, and apply it to the skin with a 10 mm diameter finchanno (-).
Apply occlusion for 4 hours and fluorescently dye the stratum corneum.Next, irradiate ultraviolet light with a maximum wavelength of 338 nm, and measure the fluorescence intensity of the stratum corneum that has been fluorescently dyed with danzyl chloride throughout the day. do.
皮膚に塗布されたダンジルクロライドの蛍光強度が、未
塗布部の蛍光強度まで減少した日数を角質層のターンオ
ーバー日数と定義すると、正常な場合は14日である。The number of days for the fluorescence intensity of danzyl chloride applied to the skin to decrease to the fluorescence intensity of the unapplied area is defined as the number of days for turnover of the stratum corneum, and the normal number of days is 14 days.
比較例−1クリーム
実施例−1の水添大豆リン脂質を除き、ロクジヨウ抽出
液Aをリボソーム化せず配合し、他は同様に調製した。Comparative Example 1 Cream A cream was prepared in the same manner except for the hydrogenated soybean phospholipid of Example 1, and Rokujiyo extract A was blended without converting it into ribosomes.
比較例−2クリーム
実施例−1の水添大豆リン脂質及びロクジヨウ抽出液A
を除き、他は同様に調製した。Comparative Example-2 Cream Example-1 Hydrogenated Soybean Phospholipid and Rokujiyo Extract A
Except for this, the others were prepared in the same manner.
試験結果
リボソーム化ロクジヨウ抽出液による表皮の角化速度正
常化試験の結果を表、1に示す6表、lから明らかな様
に、本発明のロクジヨウ抽出液配合皮膚外用剤は1表皮
の角化速度正常化に優れた新規皮膚外用剤である。Test results The results of the normalization test on the rate of epidermal keratinization using ribosome-formed Rokujiyou extract are shown in Table 1. As is clear from Table 6, the skin external preparation containing Rokujiyou extract of the present invention has a significant effect on the keratinization of the epidermis. This is a new topical skin preparation with excellent speed normalization.
長期連m試験における角質層のターンオーバー変化
※ターンオーバー日数は15名の平均値上標準偏差2)
リボソーム化オウゴン抽出液に間する試験紫外線や外的
因子で表皮の角化速度が異常に速くなった女性モニター
60名を被験者として、1グル一プ各15名づつ実施例
−2及び実施例−3、そして、下記の比較例−3、比較
例−4のクリームを2次月毎日使用させた。Changes in turnover of stratum corneum in long-term continuous m test *Turnover days are the average value of 15 subjects, standard deviation 2)
Experimental Example-2 and Example- 3, and the following creams of Comparative Example 3 and Comparative Example 4 were used every day for the second month.
2ケ月後、角質層のターンオーバーの改善度をダンジル
クロライド蛍光法にて測定した。Two months later, the degree of improvement in the turnover of the stratum corneum was measured using the Danzyl chloride fluorescence method.
膚外用剤は、角化速度正常化に優れた新規皮膚外用剤で
ある。The skin external preparation is a new skin external preparation that is excellent in normalizing the keratinization rate.
長期連用試験における角質層のターンオーバー日数
比較例−3クリーム
実施例−2の水添大豆リン脂質を除き、オウゴン抽出液
Aをリボソーム化せず配合し、他は同様に調製した。Comparative example of the number of days for turnover of the stratum corneum in a long-term continuous use test - 3 Cream Except for the hydrogenated soybean phospholipid of Example 2, Scutellaria scutellariae extract A was blended without being converted into ribosomes, and the rest were prepared in the same manner.
比較例−4クリーム
実施例−2の水添大豆リン脂質及びオウゴン抽出液Aを
除き、他は同様にlll1!シた。Comparative Example-4 Cream Except for the hydrogenated soybean phospholipid and Scutellaria scutellariae extract A of Cream Example-2, the rest was lll1! Shita.
試験結果
リボソーム化オウゴン抽出液による表皮の角化速度正常
化試験の結果を表、2に示す0表、2から明らかな様に
、本発明のオウゴン抽出液配合皮※ターンオーバー日数
は15名の平均値士標準偏差3)リボソーム化ロクジヨ
ウ抽出液象とリボソーム化オウゴン抽出液併用における
試験
年齢40歳以上の角化速度の遅い女性のうち、頬の部位
に有核細胞を認め角化速度の速い部位を併せ持ったモニ
ター60名を被験者とした。1グル一プ各15名づつ、
実施例−5及び実施例−6のクリーム、比較例−5、比
較例−6のクリームを2ケ月間毎日使用させた。Test Results The results of the epidermal keratinization rate normalization test using ribosomal Scutellaria scutellariae extract are shown in Tables 0 and 2. Average value and standard deviation 3) Among women aged 40 years or older with a slow keratinization rate, nucleated cells were observed in the cheek area and showed a fast keratinization rate. The subjects were 60 monitors with different body parts. 15 people per group,
The creams of Examples 5 and 6, Comparative Example 5, and Comparative Example 6 were used daily for two months.
2ケ月後、角質層のターンオーバーの改善度をダンジル
クロライド蛍光法にて測定した。Two months later, the degree of improvement in the turnover of the stratum corneum was measured using the Danzyl chloride fluorescence method.
試験結果
リボソーム化オウゴン抽出液及びリボソーム化ロクジヨ
ウ抽出液の併用による表皮の角化速度正常化試験の結果
を表、3に示す0表、3から明らかな様に、本発明のロ
クジヨウ抽出液及びオウゴン抽出液配合皮膚外用剤は、
角化速度の遅い部位は速く、角化速度の速い部位は遅く
し角化速度正常化に優れた新規皮膚外用剤である。Test results Table 3 shows the results of a test for normalizing the rate of epidermal keratinization using a combination of ribosomal Scutellaria scutellariae extract and ribosomal Scutellaria scutellariae extract of the present invention. Extract liquid-containing skin preparation for external use is
This is a new topical skin preparation that is excellent in normalizing the keratinization rate by speeding up the keratinization rate in areas with a slow keratinization rate and slowing down the keratinization rate in areas with a fast keratinization rate.
以下余白
比較例−5クリーム
実施例−5のクリームの水添大豆リン脂質を除き、ロク
ジヨウ抽出液A及びオウゴン抽出液Aをそのまま配合し
た。Comparative Example 5 Cream The hydrogenated soybean phospholipids in the cream of Example 5 were removed, and the Scutellaria japonica extract A and the Scutellaria scutellariae extract A were blended as they were.
比較例−6クリーム
実施例−5のクリームの水添大豆リン脂質、ロクジヨウ
抽出液A、オウゴン抽出液Aを除き、他は同様に調製し
た。Comparative Example 6 Cream A cream was prepared in the same manner as in Example 5, except for the hydrogenated soybean phospholipids, Scutellaria chinensis extract A, and Scutellaria scutellariae extract A.
表、3 長期連用試験における角質層のターンオーバー
日数
(1)角化速度の遅い部位(口元)
(2)角化速度の速い部位(頬)
(角質細胞正常化試験)
試験方法
紫外線、湿度、気温などの外的要因により、角化速度が
速くなると、角質層では本来認められない有核細胞が認
められる。そこで、この有核細胞を指標として角化速度
の改善度を測定した。Table, 3 Number of days for turnover of stratum corneum in long-term continuous use test (1) Areas with slow keratinization rate (mouth) (2) Areas with fast keratinization rate (cheeks) (keratinocyte normalization test) Test method Ultraviolet rays, humidity, When the rate of keratinization increases due to external factors such as temperature, nucleated cells that are not normally found in the stratum corneum are observed. Therefore, the degree of improvement in the keratinization rate was measured using these nucleated cells as an index.
測定方法としては、両面接着テープを、1×1cmの大
きさで貼付したスライドガラスで、洗顔後10分経過し
たモニターの顔面上に、接着面を約2秒間押しあてて、
剥離した際に採取できる角質層第1層をサンプリングし
た。スライドガラス上に採取された角質細胞は、情報に
よりヘマトキシリン・エオシン染色(H,E染色)を施
した。The measurement method was to use a slide glass with double-sided adhesive tape affixed in a size of 1 x 1 cm, and press the adhesive side for about 2 seconds on the monitor's face 10 minutes after washing the face.
The first layer of the stratum corneum, which can be collected upon peeling, was sampled. The corneocytes collected on the glass slides were stained with hematoxylin and eosin (H, E staining) according to information.
それを光学顕微鏡にて、15X20倍の倍率でヘマトキ
シリンに青く染まる有核細胞の有無を確認した。測定は
、1方向の連続した視野を5ケ所について、個数をカウ
ントした。尚、有核細胞は。The presence or absence of nucleated cells that were stained blue by hematoxylin was confirmed using an optical microscope at a magnification of 15x20. In the measurement, the number of particles was counted in five consecutive visual fields in one direction. In addition, nucleated cells.
通常クラスター状に剥離される為、以下の基準でカウン
トし、評点を与え、各々の個数との積の和をスコアーし
た。Since the flakes are usually peeled off in clusters, they were counted and given a score based on the following criteria, and the sum of the products with each number was scored.
以下余白
有角細胞評価基準
有角細胞状態
評点
単独
5個以下のクラスター
1041以上のクラスター
モニターは、有核細胞の認められた女性40名について
1グル一プ10名づつ、実施例−3及び実施例−6の乳
液、比較例−5,比較例−6の乳液について3ケ月毎日
使用 させた。Below are the margin keratinocyte evaluation criteria. Clusters of 1041 or more with 5 or less keratinocyte status scores alone are monitored by 10 people per group for 40 women with nucleated cells, according to Example-3 and The emulsions of Example 6, Comparative Example 5, and Comparative Example 6 were used daily for 3 months.
試験結果
試験結果を表、4に示す。表、4より明らかな様に実施
例−3及び実施例−6の皮膚外用剤は、有核細胞数を減
少させ、角化速度(ターンオーバータイム)を正常化さ
せる新規な皮膚外用剤である。Test Results The test results are shown in Table 4. As is clear from Table 4, the external skin preparations of Example-3 and Example-6 are novel skin preparations that reduce the number of nucleated cells and normalize the keratinization rate (turnover time). .
なお、実施例−2及び実施例−5の皮膚外用剤について
も、同様に優れた角化速度正常化作用が認められた。In addition, the skin external preparations of Examples 2 and 5 were also found to have similarly excellent keratinization rate normalizing effects.
比較例−5乳液
実施例−3の卵黄リン脂質を除き、オウガ・ン抽出液A
をリボソーム化せず配合し、他は同様に調製した。Comparative Example-5 Emulsion Excluding the egg yolk phospholipid of Example-3, Ogre Ng extract A
was prepared without converting it into ribosomes, and the other ingredients were prepared in the same manner.
比較例−6乳液
実施例−3の卵黄リン脂質及びオウゴン抽出液Aを除き
、他は同様に調製した。Comparative Example 6 Emulsion The emulsion was prepared in the same manner as in Example 3 except for the egg yolk phospholipids and Scutellaria extract A.
以下余白
表、3
長期連用試験における有核細胞数変化
※有核細胞数(スコアー)は10名の平均値士標準偏差
以上Margin table below, 3. Change in the number of nucleated cells in long-term continuous use test *The number of nucleated cells (score) is higher than the average value of 10 people and the standard deviation
Claims (3)
、皮膚表皮の角化を正常化することを特徴とする皮膚外
用剤(1) A skin external preparation that is characterized by containing ribosomes encapsulating Rokujiyou extract and normalizing the keratinization of the skin epidermis.
皮膚表皮の角化を正常化することを特徴とする皮膚外用
剤(2) Contains ribosomes containing Scutellaria extract,
External skin preparation characterized by normalizing keratinization of the skin epidermis
ゴン抽出液を内包したリボソームを配合し、皮膚表皮の
角化を正常化することを特徴とする皮膚外用剤(3) A topical skin preparation characterized by normalizing the keratinization of the skin epidermis by blending ribosomes encapsulating an extract of Scutellaria vulgare and ribosomes encapsulating an extract of Scutellariae.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63167464A JPH0818994B2 (en) | 1988-07-05 | 1988-07-05 | Topical skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63167464A JPH0818994B2 (en) | 1988-07-05 | 1988-07-05 | Topical skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0217113A true JPH0217113A (en) | 1990-01-22 |
JPH0818994B2 JPH0818994B2 (en) | 1996-02-28 |
Family
ID=15850164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63167464A Expired - Lifetime JPH0818994B2 (en) | 1988-07-05 | 1988-07-05 | Topical skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0818994B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010035070A (en) * | 2000-12-13 | 2001-05-07 | 송영응 | Composition of medicament for removing skin wrinkles and loosening of pores and manufacturing method thereof (functional cosmetics) |
JP2003028856A (en) * | 2001-07-10 | 2003-01-29 | Shiseido Co Ltd | Method and map for judgement of skin state |
JP2014141430A (en) * | 2013-01-23 | 2014-08-07 | Pias Arise Kk | AGENT FOR INHIBITING PRODUCTION OF RhoGDIβ PROTEIN, AGENT FOR CONTROLLING DIVISION DIRECTION OF EPIDERMAL CELL, SKIN LOTION, AND METHOD FOR CONTROLLING DIVISION DIRECTION OF EPIDERMAL CELL |
-
1988
- 1988-07-05 JP JP63167464A patent/JPH0818994B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010035070A (en) * | 2000-12-13 | 2001-05-07 | 송영응 | Composition of medicament for removing skin wrinkles and loosening of pores and manufacturing method thereof (functional cosmetics) |
JP2003028856A (en) * | 2001-07-10 | 2003-01-29 | Shiseido Co Ltd | Method and map for judgement of skin state |
JP2014141430A (en) * | 2013-01-23 | 2014-08-07 | Pias Arise Kk | AGENT FOR INHIBITING PRODUCTION OF RhoGDIβ PROTEIN, AGENT FOR CONTROLLING DIVISION DIRECTION OF EPIDERMAL CELL, SKIN LOTION, AND METHOD FOR CONTROLLING DIVISION DIRECTION OF EPIDERMAL CELL |
Also Published As
Publication number | Publication date |
---|---|
JPH0818994B2 (en) | 1996-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030072816A1 (en) | Agents improving skin barrier function | |
JPH07277939A (en) | Skin external preparation | |
JP3555085B2 (en) | Use of simaluba extract for reducing mottled skin pigmentation or enhancing the protective function of the skin or for preparing a skin cell medium and the composition thus obtained | |
EP0589934B1 (en) | Cosmetic or pharmaceutical, particularly dermatological, composition containing a prunella extract | |
JP4530832B2 (en) | Skin external preparation for whitening, whitening agent, whitening method, and method for producing skin external preparation for whitening | |
JPS63152309A (en) | External preparation of skin | |
TW202106323A (en) | Use ofrosmarinus officinaliscallus extract for manufacturing composition inhibiting skin aging and a culture medium for inducingrosmarinus officinaliscallus | |
CN111096915A (en) | Whitening face cleaning cream and preparation method thereof | |
JP2001114636A (en) | Hyaluronic acid production and catalase production promoting agent, fibroblast activating agent and skin lotion | |
JPH0217113A (en) | Externally applying agent for skin | |
JPH10114670A (en) | Composition suitable for external use | |
JP3522609B2 (en) | Hyaluronic acid production promoter and skin external preparation containing the same | |
TW201813629A (en) | Hydrolysate of water extract of Syzygium samarangense, and the preparation process and uses thereof | |
JPH1029922A (en) | Preparation for external use for skin | |
CN111728891A (en) | Acne mark removing composition and application thereof | |
JPH11246385A (en) | Antiaging agent | |
EP0503763A1 (en) | Cosmetic material | |
RO107544B1 (en) | Cosmetic cream | |
JPS61207321A (en) | Hair tonic | |
JP2000143527A (en) | Hyaluronic acid production promoter and skin preparation for external use containing the same | |
JP2003128573A (en) | Hyaluronic acid production stimulator, and skin care preparation containing the same | |
JP2755783B2 (en) | Cosmetics | |
JPH09309841A (en) | Preparation for external use for skin | |
CN115429712B (en) | Polypeptide and fullerene co-delivery nano composition, and preparation method and application thereof | |
JPH11116604A (en) | External preparation for skin |